I have been asked to address some of the rates of relapse and reinfection recently and wanted to reopen this thread to address it. While uncommon, relapse does occur, but the incidence is extremely low, less than 0.5%. Reinfection appears to be another issue and can usually be determined rather quickly. That doesn't mean an immune system failure, that allows the sustained viral response to falter, can't occur. It does, unfortunately, but rarely. Fortunately the new DAA's are quick to respond to this sort of issue and the advent of drug therapies, such as Vosevi, almost eliminate the concern of RAS/RAV's. Please feel free to contribute to this thread.
People with hepatitis C virus (HCV) very rarely experience a relapse of the virus following acheiving a sustained virologic response 12 weeks after completing treatment (SVR12, considered a cure), Reuters Health reports. However, certain populations of those treated for the virus are at high risk of reinfection. Publishing their findings in Clinical Infectious Diseases, researchers conducted a systematic review and meta-analysis of studies including more than 9,000 people with hep C.
I have been asked to address some of the rates of relapse and reinfection recently and wanted to reopen this thread to address it. While uncommon, relapse does occur, but the incidence is extremely low, less than 0.5%. Reinfection appears to be another issue and can usually be determined rather quickly. That doesn't mean an immune system failure, that allows the sustained viral response to falter, can't occur. It does, unfortunately, but rarely. Fortunately the new DAA's are quick to respond to this sort of issue and the advent of drug therapies, such as Vosevi, almost eliminate the concern of RAS/RAV's. Please feel free to contribute to this thread.
Risk of Late Relapse or Reinfection
People with hepatitis C virus (HCV) very rarely experience a relapse of the virus following acheiving a sustained virologic response 12 weeks after completing treatment (SVR12, considered a cure), Reuters Health reports. However, certain populations of those treated for the virus are at high risk of reinfection. Publishing their findings in Clinical Infectious Diseases, researchers conducted a systematic review and meta-analysis of studies including more than 9,000 people with hep C.
Relapse & Reinfection